ENA Respiratory Pty Ltd
ENA Respiratory is a clinical-stage pharmaceutical company dedicated to developing antiviral host defense enhancers to prevent severe respiratory viral infections. Their mission is to create broad-spectrum, virus-agnostic solutions that bolster the body's innate immune response, especially in at-risk populations such as the elderly and those with underlying health conditions. Their vision is to transform the prevention and management of respiratory viral diseases through innovative, easy-to-administer therapies that complement existing vaccines and antivirals.
Industries
Nr. of Employees
small (1-50)
ENA Respiratory Pty Ltd
Patents
Products
Clinical-stage intranasal TLR2/6 agonist prophylactic (lead candidate)
Clinical-stage small-molecule intranasal innate immune agonist developed for self-administration to locally prime and boost antiviral host-defence responses in the nasal mucosa.
Clinical-stage intranasal TLR2/6 agonist prophylactic (lead candidate)
Clinical-stage small-molecule intranasal innate immune agonist developed for self-administration to locally prime and boost antiviral host-defence responses in the nasal mucosa.
Services
Sponsorship and operational delivery of clinical studies (safety, PK/PD, proof-of-concept and multi-centre Phase II trials) for intranasal host-defence therapeutics.
Formulation optimisation, stability development and scale-up activities for intranasal drug products (dry powder and liquid) and associated device integration.
Sponsorship and operational delivery of clinical studies (safety, PK/PD, proof-of-concept and multi-centre Phase II trials) for intranasal host-defence therapeutics.
Formulation optimisation, stability development and scale-up activities for intranasal drug products (dry powder and liquid) and associated device integration.
Expertise Areas
- Clinical trial management (Phase I–II and human viral-challenge studies)
- Intranasal drug delivery and formulation (dry powder and liquid)
- Innate immunity therapeutics and TLR2/6 mechanism research
- CMC development and manufacturing scale-up for drug-device combinations
Key Technologies
- TLR2/6 agonist therapeutics (innate immune activation)
- Intranasal dry powder formulation
- Intranasal liquid spray formulation
- Animal viral challenge models (ferret, mouse)
News & Updates
ENA Respiratory announced the appointment of Kenny Simmen PhD and Alison Humbles PhD as strategic advisors to support the development of INNA-051, a broad-spectrum antiviral immune enhancer. The advisors bring extensive experience in pharma, infectious diseases, and respiratory therapies.
A peer-reviewed publication in Antiviral Research detailing the research and development of INNA-051, demonstrating its potential to prevent complications from viral respiratory infections.
ENA Respiratory was awarded a $4.38 million USD contract from the U.S. Department of Defense to support the development of INNA-051 as a broad-spectrum antiviral prophylactic.
ENA Respiratory received an additional US $3.13 million contract extension from the DOD to support inclusion of younger adults in ongoing Phase Ib study and further product development.
Research demonstrating the efficacy of INNA-051 against COVID-19 and rhinovirus, published in EBioMedicine and the European Respiratory Journal, showing significant reduction in viral levels and potential to reduce community transmission.
ENA Respiratory announced the appointment of Kenny Simmen PhD and Alison Humbles PhD as strategic advisors to support the development of INNA-051, a broad-spectrum antiviral immune enhancer. The advisors bring extensive experience in pharma, infectious diseases, and respiratory therapies.
A peer-reviewed publication in Antiviral Research detailing the research and development of INNA-051, demonstrating its potential to prevent complications from viral respiratory infections.
ENA Respiratory was awarded a $4.38 million USD contract from the U.S. Department of Defense to support the development of INNA-051 as a broad-spectrum antiviral prophylactic.
ENA Respiratory received an additional US $3.13 million contract extension from the DOD to support inclusion of younger adults in ongoing Phase Ib study and further product development.
Research demonstrating the efficacy of INNA-051 against COVID-19 and rhinovirus, published in EBioMedicine and the European Respiratory Journal, showing significant reduction in viral levels and potential to reduce community transmission.